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Experimental 
 
 
 
Strains 
 
Penicillium soppii (CBS 869.70), Penicillium jamesonlandense (CBS 102888) were obtained from CBS. A. oryzae 
NSAR1 had previously been obtained as a gift from the Kitamoto group.1 Saccharomyces cerevisiae strain 
YPH499 (Stratagene) was used for the construction of plasmids via yeast homologous recombination. Escherichia 
coli strain TOP10 (Invitrogen) was used for the standard propagation of plasmids, except when propagating 
gateway destination vectors when One Shot® ccdB Survival™ 2 T1R Competent Cells (ThermoFisher) were 
used. 
 
 
 
Culture conditions 
 
Both Penicillium strains were maintained on MEA at 25 ⁰C. A range of media were originally used to screen 
metabolite production in both strains including CYB (3.5 % Czapek-Dox Broth, 1 % Yeast Extract), MEB (Malt 
Extract Broth) and YEB (Yeast Extract Broth). Solid media of the above broths were also used, with the addition 
of 1.5 % agar. All subsequent work was done with P. soppii using CYB as the production media, cultured in 50 
ml of CYB in 250 ml flasks at 25 ⁰C with shaking at 200 rpm for 7 days. 
A. oryzae NSAR1 was maintained on MEA at 28 ⁰C. Induction medium for A. oryzae transformants was 100 ml 
CMP in 500 ml flasks (3.5% w/v Czapek Dox Broth, 2% w/v D-(+)-maltose monohydrate, 1% w/v peptone) at 
28 °C with shaking at 200 rpm for 7 days. 
 
 
 
Chemical extractions 
 
From plates 
 
Initial extractions from agar plates were based on the protocol reported by Smedsgaard.2 1 cm2 plugs of agar from 
the rim and the centre of growing colonies were treated with a solution of ethyl acetate, dichloromethane and 
methanol (3:2:1) with 1 % acetic acid. After 1 hour in an ultrasonic bath, the liquid was removed and concentrated 
under a nitrogen stream. The crude extract was then dissolved in acetonitrile to a concentration of 10 mg/mL and 
analysed by HPLC-MS/UV/ELSD. 
From liquid cultures 
 
Typical chemical extractions from fermentation cultures, both Penicillium and A. oryzae, involved adding an equal 
volume of ethyl acetate and blending to both break open the cells and thoroughly mix the culture with the solvent. 
The ethyl acetate phase was then separated, dried (using MgSO4) and evaporated under reduced pressure to give 
a crude extract. This was then dissolved in acetonitrile to a concentration of 10 mg/mL and analysed by HPLC- 
MS/UV/ELSD. 
 
 
 
LCMS analysis and purification 
 
LC-MS analysis of crude fungal extracts was conducted using a Waters LCMS system comprising of a Waters 
2767 autosampler, Waters 2545 pump system, a Phenomenex Kinetex column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) 
with a Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 1 mL/min. Detection was by Waters 
2998 Diode Array detector between 200 and 600 nm; Waters 2424 ELSD and Waters SQD-2 mass detector 
operating simultaneously in ES+ and ES- modes between 100 m/z and 800 m/z. A gradient of solvents was used 
(A, HPLC grade H2O containing 0.05% formic acid; B, HPLC grade CH3CN containing 0.05% formic acid) 
comprising: 0 min, 95 % A; 1 min, 95% A; 2 min, 60 % A; 15 min, 5% A; 17 min, 5% A; 18 min, 95% A; 20 
min, 95% A; flow rate 1 mL·min-1 
Purification of compounds was generally achieved using a Waters mass-directed autopurification system 
consisting of a Waters 2767 autosampler, Waters 2545 pump system, a Phenomenex Kinetex Axia column (5μ, 
C18, 100 Å, 21.2 × 250 mm) equipped with a Phenomenex Security Guard precolumn (Luna C5 300 Å). Flow 
rate was at 16 mL⋅  min-1. Solvent A: HPLC grade H2O + 0.05% formic acid. Solvent B: HPLC grade CH3CN 
+ 0.05% formic acid. The post-column flow was split (100:1) and the minority flow was made up with solvent A 
to 1 mL⋅  min-1 for simultaneous analysis by diode array detector (Waters 2998), evaporative light scattering 
(Waters 2424) and ESI mass spectrometry in positive and negative modes (Waters SQD-2). Detected peaks were 
collected, then combined fractions were evaporated under a flow of dry N2 gas and residues dissolved directly in 
NMR solvent for NMR analysis. 
Quantification of cycloaspeptide A 
 
To allow for quantification of cycloaspeptide A, purified cycloaspeptide A was used to produce a standard curve. 
Cycloaspeptide A concentrations and the peak integration from diode array data were found to have a linear 
relationship within the range 0.01 – 1 mg / ml with an injection volume of 10 µl (Figure S1). Thus, crude extracts 
were diluted to give a concentration in the middle of this range and standards were injected on the same analytical 
run. 
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Figure S1: The relationship between cycloaspeptide A concentration and peak area (UV chromatogram) was 
found to be linear within the concentration range of 0.01 – 1 mg / ml when the injection volume was 10 µl. 
 
 
 
 
 
Nucleic acid preparation 
 
Genomic DNA for sequencing and for strain analysis was prepared from P. jamesonlandense and P. soppii by 
harvesting mycelia which was then lyophilized and ground under liquid nitrogen before using the GenElute Plant 
Genomic DNA Miniprep kit (Sigma). RNA for cDNA production was prepared using the RNeasy kit from Qiagen 
according to the manufacturer’s instructions. cDNA was synthesised using RevertAid First Strand cDNA 
Synthesis Kit (ThermoFisher). 
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PCR 
 
Analytical PCR was performed using BioMix Red (Bioline) and preparative PCR was performed the high-fidelity 
polymerases KOD Hot Start DNA Polymerase (Merck Millipore) or KAPA HiFi DNA polymerase (Roche 
Diagnostics). 
 
 
 
Primer Table 
 
Table S1: All primers were synthesised by Sigma. 
 
 
Primer Name Sequence 5’ – 3’ 
pTub-Ps-F CTTGTCGGTCTTGGGCGCACCGGCGGACATACTCCAAATGCCACCTCCAA 
pTub-Ps-R GGTGAACAGCTCCTCGCCCTTGCTCACCATTTTGAAAAGGTATCCCAATG 
pGpdA-Ps-F TTGAGATTGATTGGAGGTGGCATTTGGAGTATGTCCGCCGGTGCGCCCAA 
pGpdA-Ps-R CTCGACAGACGTCGCGGTGAGTTCAGGCATGATTGCGGTTTACTAGAGCA 
Yeast-frag-F CACGACGTTGTAAAACGACGGCACGTGCCACCATTGCGAATACCGCTTCC 
Yeast-frag-R TAATTATATCAGTTATTACCTGCATGCCTGCAGGTCGAGTGGAGATGTGG 
YA-PscyB-F1 TAATGCCAACTTTGTACAAAAAAGCAGGCTATGTCTCAGATCAAGGTCCGA 
YA-PscyB-F2 TGGAGTCTTGTCCTATCTGC 
YA-PscyB-F3 CCAGATGATTGATACGGCTT 
YA-PscyB-F4 ACCGGATTCTCGGACAGTTC 
YA-PscyB-F5 CCATCTTCCTGATCCTAGCC 
YA-PscyB-R1 TTCCCGTCAGAGACAAATCC 
YA-PscyB-R2 TTCTGTAGCCCGGTCTGTTC 
YA-PscyB-R3 ACGGACTTGTTCCAAATGG 
YA-PscyB-R4 GCATGTTGCAGCACAAGGTC 
YA-PscyB-R5 TATAATGCCAACTTTGTACAAGAAAGCTGGTTGTCTCATCCTCAGCCGTT 
YA-PscyA-F CTTTCTTTCAACACAAGATCCCAAAGTCAAAATGCGGTACCTCACTCAAC 
YA-PscyA-R AGGTTGGCTGGTAGACGTCATATAATCATATCAGCGCGAAGCGGGATTGG 
pTYGen-G418-F GTGAAAGTAAAAGATGCTGAAGATCAGTTGTCTAGTGGATCTTTCGACAC 
pTYGen-G418- 
 
R 
TTGGAGGTGGCATTTGGAGTTCGAGTGGAGATGTGGAGTG 
pTYGen-Tub-F CACTCCACATCTCCACTCGAACTCCAAATGCCACCTCCAA 
pTYGen-Tub-R GCTGTGTTGTCGGACCTTGATCTGAGACATTTTGAAAAGGTATCCCAATG 
pTYGen-2u-R ACTGATTACTAGCGAAGCTG 
PscyD-LF TAATGCCAACTTTGTACAAAAAAGCAGGCTTATTCAAGGGTGCCTAGTGA 
PscyD-LR CGAAAGATCCACTAGAGGATCCCCATCATGCTCTGGTGAAGAGATGACAG 
PscyD-RF AGCGCCCACTCCACATCTCCACTCGACCTGCGGATCTCATGGGCTGTCA 
PscyD-RR AATGCCAACTTTGTACAAGAAAGCTGGGTTTGGACGGGTGTTTGCAATG 
PscyB-LF TAATGCCAACTTTGTACAAAAAAGCAGGCTATGTCTCAGATCAAGGTCCGA 
PscyB-LR ACTAGAGGATCCCCATCATGGAAAGACGACCAGAATTGGCA 
PscyB-RF CCACATCTCCACTCGACCTGTCGGAAGGATACACAAGTCAA 
PscyB-RR AATGCCAACTTTGTACAAGAAAGCTGGGTTCAGCCGTTAGTTAGGTCATG 
PscyA-LF TAATGCCAACTTTGTACAAAAAAGCAGGCTGCAGCCACTTAACTATGTAC 
PscyA-LR ACTAGAGGATCCCCATCATGACTAACCCAGACCCAAGTTC 
PscyA-RF CCACATCTCCACTCGACCTGGCGAATACGGTTATGGGACA 
PscyA-RR AATGCCAACTTTGTACAAGAAAGCTGGGTAGTCTGTTTCTCATTTGAGCC 
HygR1-F CATGATGGGGATCCTCTAGTG 
HygR2-R CTCCAACAATGTCCTGACG 
HygR3-F CTGTCGAGAAGTTTCTGATCG 
HygR4-R CACATCTCCACTCGACCTG 
PscyB-KOA-L GCATCAATTGGGCAATCG 
PscyB-KOA-R TGGGACCTGTCTTGTCTC 
PscyA-KOA-L ATTGTCAGCCGGTCTACCTC 
PscyA-KOA-R TTCTCGTCACTCTGGACAGT 
PscyD-KOA-L GGATTCTGCGTTGAGAGCAA 
PscyD-KOA-R TTGACATTGGCATCAACGAT 
Transformations protocols 
 
S. cerevisiae 
Transformations were performed using the LiAc PEG mediated method.3 
 
A. oryzae 
Transformations were performed using the PEG mediated protoplast method as described previously.4 
 
P. soppii 
Spores were harvested from a single, fully covered plate and incubated for 3 – 5 days at 25 °C with shaking at 200 rpm 
in 50 ml of MEB medium (Malt Extract Broth). The resulting hyphae were harvested by centrifugation (8000 x g for 10 
mins), washed once with H2O, once with 0.8M NaCl then resuspended in 10 ml of filter sterilised protoplasting solution 
(20 mg/ml Trichoderma lysing enzyme (Sigma) and 5 mg/ml driselase (Sigma) in 0.8 M NaCl). Protoplasting was left to 
proceed with gentle shaking for 2 hours. Protoplasts were filtered through sterile miracloth, harvested by centrifugation 
(3000 x g for 5 min) and washed in solution 1 (0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl pH 7.5). The protoplasts 
were then resuspended in 200-500 μl of solution 1. For each transformation, 100 μl of protoplasts and 5-10 μg (10 μl 
max) of concentrated PCR product or plasmid DNA were gently mixed. The transformation was incubated on ice for 2 
mins, after which 1 ml of solution 2 (60% (w/v) PEG 3350, 0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl pH 7.5) was 
added and then incubated at room temperature for 20 mins. To plate out, 5 ml of molten (50 °C) MEA/S top medium (2% 
(w/v) malt extract broth, 1 M sorbitol, 0.8% (w/v) agar) was added, gently mixed and then overlaid onto prepared plates 
(2% (w/v) malt extract broth, 1 M sorbitol, 1.5% (w/v) agar). Plates were then incubated at 28 °C for 3 days, or until 
colonies appeared. 
Gene knock-outs 
 
Various genes were disrupted in this work using the bipartite gene knock-out approach. This approach involves splitting 
the selectable marker into two overlapping fragments, each of which are fused to regions homologous to the region to be 
targeted. (with a ~500 bp overlap). The splitting of the selectable marker means that homologous recombination is 
required to reconstruct the cassette and allow selection, which in turn improve the frequency of integration via 
homologous recombination, and thus gene disruption. 
Gene knock-out cassettes were constructed in plasmid pE-YA and subsequently used as templates to produce the DNA 
fragments required for the bipartite knock-out method. The general approach is outlined in Figure S2. 
Three knock-out cassettes were constructed for the cycloaspeptide N-methyltransferase PscyA, NRPS PscyB and the 
transcription factor PscyD. The right and left flanking regions for each were amplified from P. soppii genomic DNA 
using the following primer pairs: 
PscyB-LF/PscyB-LR and PscyB-RF/PscyB-RR for the left and right flanking regions of PscyB. 
PscyA-LF/PscyA-LR and PscyA-RF/PscyA-RR for the left and right flanking regions of PscyA. 
PscyD-LF/PscyD-LR and PscyD-RF/PscyD-RR for the left and right flanking regions of PscyD. 
The primer pair HygR1-F/HygR4-R was used to amplify the hygromycin cassette which formed the centre of the knock- 
out construct. To amplify the bipartite fragments for the transformation, the forward primer for the left flanking region 
(PscyA-LF, PscyB-LF or PscyD-LF) was combined with the primer HygR2-R, and HygR3-F was combined with the 
reverse primer for the right flanking region (PscyA-RR, PscyB-RR or PscyD-RR). 
 
 
 
 
 
 
 
Figure S2: The knockout cassettes consist of the hygromycin resistance cassette, which consists of the gpdA promoter, 
the HygR resistance gene and the trpC terminator (reference), flanked by approximately 1 kb fragments of the gene to be 
targeted. Once this cassette has been constructed in yeast, the overlapping bipartite fragment can be amplified from the 
resulting plasmid, either directly from the yeast plasmid preparation, or after passage through E. coli. 
Once transformants had been generated using the bipartite method, targeted integration of the knock-out construct was 
tested by using primers designed to bind outside the homologous regions in combination with primers which bind within 
resistance cassette (Figure S3). Correct integration at the left-hand side of the targeted region was tested using the primer 
HygR2-R in combination with either PscyA-KOA-L, PscyB-KOA-L or PscyD-KOA-L. Correct integration at the right- 
hand end of the region was tested using primer HygR3-F with the gene specific primers PscyA-KOA-R, PscyB-KOA-R 
or PscyD-KOA-R. 
 
 
 
Figure S3: Correct integration of knock-out cassettes was confirmed by combining primers designed to bind outside the 
targeted region with primers binding within the resistance cassette. 
H. virescens injection assay 
 
Intrinsic insecticidal activity was determined by administering peptides via injection (33 gauge needle) into the 
haemolymph of early fourth instar tobacco budworm, Heliothis virescens. The injection was made into the second 
abdominal segment between the subdorsal band and spiracular band. 
Insecticidal activity of the peptides was compared to Spinosad (positive control) and neat dimethyl sulfoxide DMSO 
(negative control). There were six replicates per treatment. 1µl of each treatment was injected per larva. 
Cycloaspeptide E 5 and 4-fluoro phenylalanine Cycloaspeptide E were solubilised in DMSO at 10 mg ml-1. Spinosad was 
solubilised in DMSO at 0.19 mg ml-1. 
Visual assessments of mortality were made at 1, 2, 3 and 7 days after injection for each treatment. 
 
 
 
 
Genome Sequencing and Bioinformatics 
 
Genome sequences were obtained for both Penicillium strains using Illumina MiSeq with a 600-cycle (2x300 bp) kit, and 
assembled and annotated using Newbler v29. The statistics for the two resulting genome sequences are shown in Table 
S2. 
Table S2: Genome statistics 
 
Penicillium jamesonlandense Penicillium soppii 
Estimated Genome Size 38.1 Mbp 33.4 Mbp 
Number of Scaffolds 235 300 
Largest Scaffold 3,085,890 1,305,324 
Scaffold N50 1,142,055 451,138 
Total Scaffold Length 35.8 Mbp 32.6 Mbp 
Number of Contigs 697 687 
Largest Contig 1,181,107 788,536 
Contig N50 376,897 276,214 
Total Contig Length 35.8 Mbp 32.7 Mbp 
Mapping-rate 94.0 % 97.5 % 
An initial AntiSMASH5 analysis was conducted on both genomes to identify putative secondary metabolite gene clusters 
(Table S3). 
Table S3: The number of gene clusters of different types within the genomes of P. soppii and P. jamesonlandense, as 
analysed by antiSMASH. 
CLUSTER TYPE P. SOPPII P. 
 
JAMESONLANDENSE 
NRPS 20 17 
PKS 16 13 
PKS-NRPS 6 6 
Terpene 4 2 
Terpene-PKS-NRPS 1 0 
Terpene-NRPS 0 1 
Other 17 14 
Putative 18 30 
Total 82 83 
 
 
 
 
 
Identification of homologues to known clusters 
 
 
In addition to searching the genomes of P. soppii and P. jamesonlandense for putative cycloaspeptide clusters, 
homologues to the clusters known to be involved in other compounds were searched for, including the pseurotin A, 
fumagillin, griseofulvin and kojic acid clusters. 
This was done by blasting our genomic databases for homologues to biosynthetic genes previously reported and available 
through NCBI. The results of those blast searches were cross-referenced with the antiSMASH predictions for each 
genome and putative gene clusters were then fully annotated in Artemis using FGENESH predictions and manual editing 
based on alignments with known homologues (Figures S4 –S6). 
  
 
 
Figure S4: The pseurotin and fumagillin superclusters identified within the genomes of P. soppii and P. jamesonlandense. These clusters are homologous to the gene 
cluster identified in A. fumigatus6, in both gene content and gene organisation. 
  
 
 
 
 
Figure S5: Homologues for the griseofulvin gene cluster from Penicillium aethiopicum7 were identified within 
the genomes of P. soppii and P. jamesonlandense. The P. jamesonlandense gene cluster is lacking homologues 
to GsfK, a dehydrogenase encoding gene, and GsfR2, a transcription activator-encoding gene. We have not 
observed Griseofulvin production in this strain so it is possible that this cluster is no longer functional. 
 
 
 
 
 
 
Figure S6: A putative kojic acid gene cluster was identified within the genome of P. soppii, but not P. 
jamesonlandense. Homologues to the known Kojic acid genes of A. oryzae; KojT, KojR and KojA,8 were 
identified. In addition, two genes which may be involved in secondary metabolite biosynthesis; an isomerase and 
dehydrogenase, were identified adjacent. 
Identification and analysis of the cycloaspeptide gene cluster 
 
 
The domain structures of all NRPS encoding genes in the two Penicillium genomes were analysed using InterPro 
(EMBL) (Table S4). This identified one NRPS (NRPS11) as being common to both species and having the correct 
number of modules for producing a pentapeptide (Figure S7). 
Table S4: Domains present in predicted NRPSs encoded by genes within the genomes of P. soppii and P. 
jamesonlandense. A total of 11 NRPS genes, present in 8 separate gene clusters, were common to both species. 
A: Adenylation domain. C: Condensation domain. PCP: Phosphopantetheine attachment site. NR: an NRPS 
domain (domain TIGR01720) though to be involved in post-condensation modification. TE: Termination 
thioesterase domain. 
GENE CLUSTER DOMAINS 
 
NRPS1 P. soppii P. james. A PCP C NR TE 
NRPS2 Cl5 Cl11 3 3 4 1  
NRPS3 Cl13 Cl15 2 2 2   
NRPS4 Cl20 Cl49 4 5 6 2  
NRPS5 
NRPS6 
NRPS7 
Cl31 Cl44 1 1 -  1 
2 2 1  1 
2 2 2   
NRPS8 Cl62 Cl48 2 2 2   
NRPS9 Cl67 Cl47 3 5 6   
NRPS10 Cl68 Cl61 3 3 2  1 
NRPS11 Cl82 Cl10 5 5 5   
NRPS12 
NRPS13 
NRPS14 
Cl14 
 
 
Cl21 
- 
 
 
- 
2 
 
1 
 
1 
2 
 
1 
 
2 
2 
 
1 
 
2 
  
NRPS15 Cl24 - 2 2 2   
NRPS16 Cl27 - 4 4 5 1  
NRPS17 Cl36 - 2 2 2   
NRPS18 Cl56 - 4 4 6 1  
NRPS19 Cl59 - 4 4 5 1  
NRPS20 Cl73 - 2 2 2   
NRPS21 Cl76 - 4 4 5 1  
NRPS22 Cl78 - 3 3 3  
NRPS23 Cl80 - 1 3 3  
NRPS24 Cl81 - 3 3 3  
NRPS25 - Cl7 4 4 6 1 
NRPS26 - Cl22 4 5 6 1 
NRPS27 - Cl35 7 8 8  
NRPS28 - Cl58 2 3 2  
NRPS29 - Cl65 2 2 2  
NRPS30 - Cl66 2 2 2  
NRPS31 - Cl79 1 1 1  
NRPS32 - Cl82 3 3 3 1 
NRPS33 - Cl83 1 1 1  
 
 
 
 
 
Figure S7: The predicted domain architecture of NRPS11, as analysed using InterPro9. This NRPS is present in 
both the P. jamesonlandense and P. soppii genomes, named PjcyB and PscyB respectively, and is responsible for 
cycloaspeptide biosynthesis. 
 
 
The putative gene clusters containing NRPS11 from both species were annotated using Softberry to predict the 
intron and exon positions for coding sequences. This annotation was then manually adjusted using discretion, 
based on alignments with homologues identified during blast searches. Putative gene functions were then 
investigated using BLAST and InterPro. 
 
The antiSMASH predicted gene cluster for P. soppii contained only two genes, a putative N-methyltransferase 
encoding gene (named PscyA) and NRPS11 (PscyB). The antiSMASH predicted cluster for P. jamesonlandense 
was significantly larger, containing homologues to PscyA and PscyB (named PjcyA and PjcyB respectively) and 
encoding a putative amidase (PjcyC), a transcription factor (PjcyD), an amino acid transporter (PjcyF) and an 
aminotransferase (PjcyG) (Figure S8). Searching the P. soppii genome for homologues to these additional genes 
identified them all together, but at a different genomic locus, with a genomic comparison conducted using artemis 
comparison tool suggesting that a genomic region containing the N-methyltransferase and NRPS (PscyA and 
PscyB) has undergone a translocation event in P. soppii at some point during the species divergence. An additional 
gene, PscyE, encoding a putative dehydrogenase, was present in P. soppii but absent in P. jamesonlandense. 
A bioinformatic analysis of the genes in both species is shown in Table S5. Closest homologues were identified 
using the blastp algorithm to search the Swiss-Prot protein database. 
 
 
 
 
 
 
Figure S8: An ACT comparison of putative cycloaspeptide biosynthetic genes present in the genomes of P. 
jamesonlandense and P. soppii. Homology between the predicted protein sequences (using the tblastx algorithm) 
is denoted by the red bars. In P. jamesonlandense the 6 genes are all located at one locus. In P. soppii they are 
split over two loci. 
  
 
 
Table S5: A bioinformatic analysis of the genes identified within the predicted cycloaspeptide gene clusters of P. soppii and P. jamesonlandense. Predicted gene function is 
based on homologues identified during BLAST searches. Domains were identified using the NCBI Conserved Domain Search.10 The closest homologues, identified by blasting 
the predicted protein sequences against the Swiss-Prot database, are shown. 
 
Gene name 
(P. james / 
P. soppii) 
Predicted gene 
function 
 
Gene Size 
 
Introns 
Protein 
Size 
 
Domains 
 
Homologue 
Identity 
(%) 
 
E value 
Query 
Coverage 
 
Score 
PjcyA / PscyA 
N- 
methyltransferase 
1153/1096 1/1 366/347 
Methyltransf_33: 
pfam10017 
dtpB11 38%/39% 2e-82/2e-82 94%/96% 254/254 
PjcyB / PscyB NRPS 17013/17007 0/0 5670/5668 See Figure S7 easA12 33%/33% 0.0/0.0 97%/96% 2399 /2370 
PjcyG /PscyG Amidase 2079/2079 0/0 692/692 
Amidase: 
pfam01425 
- - - - - 
 
 
PjcyD / PscyD 
 
Transcription 
factor 
 
 
1768/1777 
 
 
2/2 
 
 
559/556 
GAL4: cd00067 
Fungal_trans_2: 
 
pfam11951 
 
ustR13 
 
 
26%/25% 
 
 
9e-44/1e-46 
 
 
94%/98% 
 
 
164/172 
- / PscyE Dehydrogenase 1687 3 491 - - - - - - 
PjcyF / PscyF 
Amino acid 
transporter 
1416/1392 0/0 471/463 
Aa_trans: 
pfam01490 
mtr14 54%/53% 
2e-162/2e- 
163 
92%/94% 467/469 
PjcyC / PscyC Aminotransferase 1116/1116 0/0 371/371 
Aminotran_1_2: 
  pfam00155  
His515 28%/28% 2e-10/3e-10 52%/52% 62/61.2 
 
 
Construction of plasmids 
 
All plasmids used in this work were built by yeast recombination, where S. cerevisiae was transformed with 
approximately 0.5 μg of each required DNA fragment, with at least 30 bp homologous overlap between adjacent 
linear fragments to be joined. Resulting plasmids were extracted from yeast using the Zymoprep™ Yeast Plasmid 
Miniprep II kit, according to the manufacturer’s instructions and then transformed into commercially available 
One Shot TOP10 Chemically Competent E. coli to obtain sufficient plasmid copies for downstream applications. 
 
 
 
pTHPs-eGFP 
 
This plasmid is an adapted version of pTYGS-eGFP, an A. oryzae plasmid provided by the group of Dr. Colin 
Lazarus, which contains a hygR cassette (conferring hygromycin resistance) as the selectable marker, and an eGFP 
cassette to function as a reporter gene. In the original plasmid, these cassettes contain the A. oryzae GpdA and 
AmyB promoters respectively. A strategy was designed to replace these promoters with the GpdA and tubulin 
promoters from P. soppii, which were amplified from genomic DNA using primers pGpdA-Ps-F/pGpdA-Ps-R 
and pTub-Ps-F/pTub-Ps-R respectively. A portion of the yeast shuttle vector, pE-YA, containing the 2u Ori and 
Ura3 cassette for uracil prototrophy, was also amplified using primers Yeast-frag-F/Yeast-frag-F and recombined 
into the plasmid, simultaneously converting the plasmid into a yeast/E. coli shuttle vector and allowing the yeast 
recombination to occur. pTYGS-eGFP was digested with HindIII, XhoI and NotI prior to recombination. 
  
Figure S9: pTHGS-eGFP, an A. oryzae plasmid, was converted for use in P. soppii by replacing the promoter 
regions (pgpdA and pamyB) with native P. soppii promoters (pGpdA-Ps and pTub-Ps). This was achieved in one 
step by introducing the required cassettes for plasmid function in yeast (Ura3 and the 2u Ori) at the same time as 
swapping the promoters by yeast homologous recombination. 
 
 
pTYGS-N-Met-NRPS 
 
The large (17007 bp) NRPS encoding gene PscyB was amplified from genomic DNA in five overlapping 
fragments of approximately 3.5 kb each using the primer pairs YA-PscyB-F and YA-PscyB-R, numbered 1 to 5. 
These fragments were homologous recombined in yeast to reconstruct the full NRPS in the plasmid pE-YA. 
Simultaneously, the N-Methyltransferase PscyA was amplified using the primer pair YA-PscyA-F/YA-PscyA-R 
from P. soppii cDNA generated under cycloaspeptide production conditions (due to the presence of an intron). 
The resulting coding sequence was recombined into the multi-gene expression vector pTYGS-arg16 so that it is 
located between an A. oryzae promoter (Padh) and terminator (Teno). PscyB was then transferred into the PscyA 
containing plasmid using gateway technology to produce the final vector: pTYGS-N-Met-NRPS (Figure S10). 
  
Figure S10: The construction of pTYGS-N-Met-NRPS. The N-methyltransferase PscyA was transferred, via yeast 
recombination, into a multigene expression vector with arginine prototrophy called pTYGS-Arg. This placed 
PscyA between the A. oryzea alcohol dehydrogenase promoter (pAdh) and the A. oryzae enolase terminator (tEno). 
The NRPS gene, having been reconstructed from 5 PCR products in a yeast assembly vector, pE-YA, was then 
transferred into the expression vector using Gateway technology. 
 
 
pTYGen-N-Met-NRPS 
 
 
 
To adapt pTYGS-N-Met-NRPS for use in the P. soppii NRPS knock-out strain, the argB cassette, which confers 
arginine prototrophy to A. oryzae NSAR1, was replaced with the nptII cassette, which confers resistance to the 
antibiotic geneticin. The promoter driving expression of the NRPS was also converted from the A. oryzae AmyB 
promoter to the P. soppii tubulin promoter. The nptII cassette was amplified from a geneticin plasmid using 
primers pTYGen-G418-F and pTYGen-G418-R. The tubulin promoter was amplified from plasmid pTYPs-eGFP 
using the primer pair pTYGen-Tub-F/pTYGen-Tub-R. SnaBI was used to digest pTYGS-N-Met-NRPS, but in 
addition to cutting within the region to be modified, this enzyme also cuts within the N-methyltransferase cassette 
and the 2u origin of replication. Therefore, a portion of the original plasmid spanning both of these restriction 
sites was amplified using the primers YA-PscyA-F and pTYGen-2u-R, to act as a patch during the yeast 
recombination. These various fragments (SnaBI digested pTYGS-N-Met-NRPS, the geneticin cassette, the tubulin 
promoter and the patch fragment) were transformed into S. cerevisiae and the resulting plasmid, named pTYGen- 
N-Met-NRPS was extracted from yeast and propagated in E. coli. 
 
 
 
 
Figure S11: pTYGS-N-Met-NRPS, a plasmid constructed to produce cycloaspeptides in A. oryzae, was converted 
for use in P. soppii, to compliment an NRPS knock-out strain. This was achieved by replacing the argB cassette 
(for arginine prototrophy in A. oryzae), with the nptII cassette (for geneticin resistance), and replacing the A. 
oryzae amyB promoter with the P. soppii tubulin promoter. 
 
 
 
 
 
LCMS data 
 
Initial LCMS analysis using the Waters LCMS system with a Phenomenex Kinetex column allowed detection of 
compounds via their mass and UV spectra. Data from this analysis is shown below for the various cycloaspeptides 
and the ditryptophenaline compounds (Figures S12 to S20). 
  
Figure S12: LCMS analysis of cycloaspeptide A 1 (molecular weight: 641.77) showing ES- and ES+ mass data 
and the UV absorbance. 
 
 
 
 
 
 
 
 
 
Figure S13: LCMS analysis of cycloaspeptide B 2 (molecular weight: 627.74) showing ES- and ES+ mass data 
and the UV absorbance. 
  
Figure S14: LCMS analysis of cycloaspeptide C 3 (molecular weight: 627.74) showing ES- and ES+ mass data 
and the UV absorbance. 
 
 
 
 
 
 
Figure S15: LCMS analysis of cycloaspeptide E 5 (molecular weight: 625.77) showing ES- and ES+ mass data 
and the UV absorbance. 
 
 
Figure S16: LCMS analysis of cycloaspeptide G 7 (molecular weight: 657.77) showing ES- and ES+ mass data 
and the UV absorbance. 
 
 
 
 
 
 
 
 
 
Figure S17: LCMS analysis of 4F-cycloaspeptide B 21 (molecular weight: 645.73) showing ES- and ES+ mass 
data and the UV absorbance. 
 
 
Figure S18: LCMS analysis of 4F-cycloaspeptide E 22 (molecular weight: 661.75) showing ES- and ES+ mass 
data and the UV absorbance. 
 
 
 
 
 
 
Figure S19: LCMS analysis of ditryptophenaline 23 (molecular weight: 692.82) showing ES- and ES+ mass data 
and the UV absorbance. 
  
Figure S20: LCMS analysis of 4-fluoro-ditryptophenaline 24 (molecular weight: 729.3) showing the ES+ mass 
data. There wasn’t sufficient material within the crude extract analysed to obtain clear ES- or UV data for this 
compound using the Waters system. High-resolution masses were obtained using the orbitrap to support the 
identification of this compound (see next section). 
 
 
 
 
Figure S21: HPLC (DAD, 210–800 nm) chromatograms comparing P. soppii crude extracts grown in yeast 
extract broth (YEB), malt extract broth (MEB) or Czapek yeast broth (CYB) for 13 days at 25 ⁰C with 200 rpm 
shaking. Cycloaspeptide A 1 can be clearly seen in all cultures at 17.7 minutes. 
  
Figure S22: HPLC analysis of the crude extract from P. soppii grown on MEB. From the top; ELSD, ES-, ES+ 
and UV spectra. The masses of peaks A and B correspond to pseurotin A. Peak E is cycloaspeptide A 1. The mass 
of peak F corresponds to benzomalvin A. The mass of peak G corresponds to fumagillin. The accurate masses of 
these peaks have been shown to correspond to the molecular formulae of these compounds (see Figure S26 and 
Table S6). 
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B C D 
H 
F 
  
Figure S23: HPLC analysis of the crude extract for P. jamesonlandense grown in MEB for 14 days. ELSD, ES-, 
ES+ and UV (from the top). Peak A is pseurotin A. The mass of peak B corresponds to cycloaspeptide G 7. Peak 
D is cycloaspeptide A 1. The mass of peak C corresponds to cycloaspeptide D 4. The mass of peak E corresponds 
to fumagillin. The accurate masses of these peaks have been shown to correspond to the molecular formulae of 
these compounds (see Figure S27 and Table S7). 
D 
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Figure S24: An extracted ion chromatogram for the mass of cycloaspeptide A 1 ([M-H]-: 641.7), comparing P. 
soppii wild-type (top trace) and six transcription factor knock-out lines (PscyD) grown on MEA. A reduction or 
total loss of cycloaspeptide production is seen in all transformants. 
 
High-Resolution Accurate Mass data 
 
Various crude extracts were analysed using an Orbitrap Elite system (Thermo Scientific) to obtain high-resolution 
mass-spec data and the resulting predicted formulae. 
Pencillium species 
 
Figure S25: Orbitrap mass spectrum of P. soppii crude extract, grown in MEB for 2 weeks at 25⁰C with 200 rpm 
shaking. The MS data for this spectrum is shown in Table S6. 
Table S6: Summary of the main peaks detected by the Waters LC-MS system and UPLC-Orbitrap Mass Analyser 
from a P. soppii MEB crude extract (2 weeks at 25 ⁰C with 200 rpm shaking) 
P. soppii extract 
 HPLC- 
 
MS/UV/ELSD 
   UPLC-Orbitrap  
peak RT 
 
(min) 
ES+ ES- UV (nm) ELSD RT 
 
(min) 
ES+ Formula Suggested 
 
Compound 
A 11.7 432 430 258, 385  7.0 454.1470 C20H19O6N7 pseurotin A 
B 12.2 432 430 258, 385  7.4 454.1470 C20H19O6N7 pseurotin A 
C 12.5 316 314 258 
 
290 
    - 
D 15.1 405 381 - -    - 
E 17.7 642 640 258, 
 
307 
 12.0 642.3288 C36H43O6N5 cycloaspeptide A 
F 17.9 382, 
 
404 
- 300  11.1 382.1503 C37H39O3N9 benzomalvin A 
G 19.0 458, 
 
481 
- 300    fumagillin 
H 19.4 458, 
 
481 
- 300      
I      10.1 658.3243 C36H43O7N5 cycloaspeptide G 
  
Figure S26: Orbitrap mass spectrum of P. jamesonlandense crude extract, grown in MEB for 2 weeks at 19 ⁰C 
with 200 rpm shaking. The MS data for this spectrum is shown in Table S7. 
 
 
 
Table S7: Summary of the main peaks detected by the Waters LC-MS system and UPLC-Orbitrap Mass Analyser 
from a P. jamesonlandense MEB crude extract (2 weeks at 19 ⁰C with 200 rpm shaking) 
 
P. jamesonlandense extract 
 HPLC- 
 
MS/UV/ELSD 
   UPLC-Orbitrap  
peak RT 
 
(min) 
ES+ ES- UV (nm) ELSD RT 
 
(min) 
ES+ Formula Suggested 
 
Compound 
A 11.6 432 430 258, 385  7.1 454.1470 C20H19O6N7 pseurotin A 
B 15.2 658 656 255, 290  10.14 658.3243 C36H43O7N5 cycloaspeptide G 
C 16.3 628 626 255, 300  10.97 628.3131 C35H41O6N10 cycloaspeptide D 
D 17.7 642 640 258, 307  12.02 642.3288 C36H43O6N5 cycloaspeptide A 
E 18.9 460 458 337, 352     fumagillin 
F      15.1 626.3335 C36H43O5N5 cycloaspeptide E 
A. flavus 
 
Crude extracts from various Aspergillus flavus cultures were analysed using the orbitrap system to obtain high 
resolution mass data. A compound with the exact mass of 693.31843 was detected in the wild-type cultures and 
the dtpB cultures fed with N-methylated phenylalanine, but absent from the cultures fed with 4-fluoro- 
phenylalanine. A compound with the exact mass of 729.29999 was uniquely detected in all three cultures fed with 
4-fluoro-phenylalanine. These two accurate masses correspond to the chemical formulae C42H41N6O4 and 
C42H39F2N6O4 respectively, which are the formulae for the protonated molecular ions ([M+H]
+) of 
ditryptophenaline and 4F-ditryptophenaline. 
Isolated compounds 
 
General Experimental 
 
NMR experiments were conducted on the following spectrometers: Varian 400-MR Varian (1H NMR at 400 MHz 
and 13C NMR at 100 MHz), Varian VNMR S500 spectrometer, (1H NMR at 500 MHz, 19F NMR at 470 MHz and 
13C NMR at 125 MHz) and Bruker Advance III HD Cryo 13C-probe, (1H NMR at 500 MHz and 13C NMR at 125 
MHz). Chemical shifts were recorded in parts per million (ppm referenced to the appropriate residual solvent 
peak) and coupling constant (J) in Hz, reported to the closest 0.5 Hz. Multiplicity is described by the following 
abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplets. 
 
 
The mass analyser detectors used were electrospray ionization (ESI) mass spectra, recorded on a MicrO-ToF II 
Bruker Daltonics mass spectrometer and Orbitrap Elite Thermo Scientific mass spectrometer. 
 
 
Cycloaspeptide A 1 
 
 
 
 
Cycloaspeptide A 1 was purified as white solid (1.3 mg); UV λmax nm 257, 300; 1H NMR (CDCl3, 500 MHz) 
Table S8; 13C NMR (CDCl3, 125 MHz) δC  173.70, 169.90, 169.69, 168.21, 168.15, 154.58, 141.75, 137.77, 
134.44, 130.80, 130.48,  129.52,  129.31, 127.37, 127.01,  122.42,  121.09, 115.78, 115.25,  77.41, 77.36, 77.16, 
 
76.91, 70.04, 63.46, 48.89, 44.13, 41.40, 34.17, 32.23, 30.22, 29.86, 25.00, 23.43, 22.12, 16.56; HRMS m/z 
 
calculated for C36H43N5O6 641.32134; observed m/z 642.32999. 
Table S8: 1H NMR data for purified cycloaspeptide A 1 compared to the published data17 
1H NMR of the Purified Compound 1H NMR Literature 
Residue Position δ / ppm J / Hz δ / ppm J / Hz 
Ala NH 6.59 (1H) d 7.0 6.96 (1H) d 6.96 
 CHα 4.41 (1H) m 4.41 (1H) m 
 CHβ 0.42 (3H) d 6.5 0.40 (3H) d 6.6 
Phe NCH3 2.88 (3H) s 2.87 (3H) s 
 CHα 5.20 (1H) dd 3.0, 12.0 5.21 (1H) dd 3.4, 11.7 
 CHβ 2.95 (1H) dd 12.0, 14.5 2.96 (1H) dd 12.2, 13 
  3.48 (1H) dd 4.4, 14.5 3.48 (1H) dd 4, 14.2 
 C2 C6 7.17 (2H) m 7.17 (2H) d 8.2 
 C3 C5 7.32 (2H) m 7.33 (2H) m 
 C4 7.26 (1H) m 7.26 (1H) m 
Leu NH 7.13 (1H) d 8.5 7.30 (1H) d 7.8 
 CHα 4.72 (1H) m 4.72 (1H) ddd 8, 8, 8 
 CHβ 1.36 (1H) m 1.36 (1H) ddd 5.5, 8, 13 
  1.86 (1H) ddd 5.5, 8.0, 14.0 1.86 (1H) ddd 5.5, 8.5, 13 
 CHγ 1.67 (1H) m 1.67 (1H) m 
 CH3 1.02 (3H) d 6.5 0.98 (3H) d 6.4 
Tyr NCH3 2.73 (3H) S 2.69 (3H) s 
 CHα 3.80 (1H) dd 4.0, 14.0 3.80 (1H) dd 4, 11.3 
 CHβ 3.37 (1H) dd 11.0, 14.0 3.35 (1H0 dd 11.3, 14.2 
  3.49 (1H) dd 4.0, 14.0 3.48 (1H) dd 4, 14.2 
 C2 C6 7.04 (2H) d 8.0 6.98 (2H) d 8.6 
 C3 C5 6.79 (2H) d 8.0 6.79 (2H) d 8.6 
ABA NH 12.01 (1H) s 12 (1H) s 
 C3 7.42 (1H) d 8.5 7.44 (1H) d 7.8 
 C4 7.00 (1H) t 8.0 6.96 (1H) t 7.8 
 C5 7.49 (1H) t 8.5 7.46 (1H) t 8.6 
 C6 8.92 (1H) d 8.0 8.83 (1H) d 8.6 
 
 
 
Figure S27: Proton NMR spectra for cycloaspeptide A 1, purified from P. soppii 
 
Cycloaspeptide E 5 
 
 
 
 
P. soppii ΔpscyA strain was grown in CYB (10 ×100 mL flasks), fed with N-methylphenylalanine (100 mg) and 
extracted after 14 days. The crude extract was purified using preparative HPLC using Method 1 to obtain 
cycloaspeptide E 5 as a white solid (1.3 mg); λmax / nm 257, 300; δH (CDCl3, 500 MHz) Error! Reference source 
ot found.; δC (CDCl3, 125 MHz) Table S9; m/z (ESI) 626.5862 [M+H]+ (C36H44N5O5 requires 626.3264). Data in 
accordance with the literature.180 
  
Table S9: NMR data for cycloaspeptide E 5, isolated from P. soppii strain NM-KO4 (PscyF) fed with N-methyl- 
L-phenylalanine, compared to the literature data (a500 MHz and b126 MHz, CDCl3).
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   Isolated  Literature 
Residue Position 
b 
δC / ppm δH
a / ppm (J in Hz) δC / ppm δH/ ppm (J in Hz) 
Ala NH  6.77 (1H, d, J 7.0)  6.60 (1H, d, J = 7.0 Hz) 
 Cα 44.1 4.41 (1H, m) 44.4 4.41 (1H, dq, J = 7.0, 6.6 Hz) 
 Cβ 16.5 0.41 (3H, d, J 7.0) 16.8 0.43 (3H, d, J = 6.6 Hz) 
 CO 173.9 - 173.9  
 N-Me 30.3 2.87 (3H, s) 30.4 2.89 (3H, s) 
 Cα 63.5 5.20 (1H, dd, J 12.0, 3.0) 63.7 5.21 (1H, dd, J = 11.8, 3.0 Hz) 
 Cβ 34.2 3.49 (1H, dd, J 14.0, 3.0) 34.4 3.49 (1H, dd, J = 14.3, 2.6 Hz) 
   2.96 (1H, dd, J 15.0, 12.0)  3.0 (1H, dd, J = 14.9, 12.3 Hz) 
Phe(1) C1 138.8 - 139.1  
 C2-5 129 7.36-7.28 (4H, m) 129 7.36-7.28 (4H, m) 
 C6 127 7.35 (1H, m) 127 7.35 (1H, m) 
 CO 168.1 - 168.3  
 NH  7.14 (1H, m)  7.14 (1H, d, J = 8.7 Hz) 
 Cα 48.9 4.72 (1H, ddd, J 9.0, 9.0, 6.0) 48.8 4.72 (1H, ddd, J =8.5, 8.5, 5.6 Hz) 
 Cβ 41.4 1.86 (1H, m) 41.7 1.88 (1H, m) 
   1.35 (1H, m)  1.38 (1H, m) 
Leu Cγ 25.0 1.69 (1H, m) 25.2 1.71 (1H, m) 
 Cδ 23.4 1.01 (3H, d, J 6.0) 23.7 1.02 (3H, d, J = 6.7 Hz) 
 Cε 22.1 1.00 (3H, d, J 6.0) 22.4 1.01 (3H, d, J = 6.7 Hz) 
 CO 170.0 - 170.2  
 N-Me 39.2 2.68 (3H, s) 39.5 2.70 (3H, s) 
 Cα 70.0 3.86 (1H, dd, J 11.0, 4.0) 70.0 3.87 (1H, dd, J =10.8, 3.7 Hz) 
 Cβ 33.2 3.59 (1H, dd, J 14.0, 4.0) 33.4 3.62 (1H, dd, J =13.8, 4.1 Hz) 
   3.47 (1H, dd, J 14.0, 11.0)  3.47 (1H, dd, J =14.3, 11.3 Hz) 
Phe(2) C1 137.7 - 138.1  
 C2-5 129 7.36-7.28 (4H, m) 129 7.36-7.28 (4H, m) 
 C6 127 7.35 (1H, m) 127 7.35 (1H, m) 
 CO 170.0 - 171.0  
 NH  12.03 (1H, s)  12.03 (1H, s) 
 C1 115.3 - 115.4  
ABA C2 141.7 - 142  
 C3 121.1 8.92 (1H, d, J 9.0) 121.4 8.95 (1H, d, J =8.7 Hz) 
 C4 134.5 7.51 (1H, m) 134.7 7.51 (1H, dd, J =8.7, 8.2 Hz) 
 C5 122.5 7.02 (1H, dd, J 8.0, 8.0) 122.7 7.02 (1H, dd, J =8.2, 8.2 Hz) 
 C6 127.0 7.45 (1H, d, J 8.0) 127.2 7.45 (1H, d, J =8.2 Hz) 
 CO 169.7  170.0  
4F-cycloaspeptide E 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P. soppii ΔpscyA strain was grown in CYB (5 ×100 mL), fed with m-fluoro-N-methylphenylalanine 20 (5 mM 
final concentration) and extracted after 14 days. The crude extract was purified by preparative HPLC using Method 
1 to obtain 4F-cycloaspeptide E 22 as a white solid (1.3 mg); λmax / nm 257, 300; δH (CDCl3, 500 MHz) Table 
S10; δC (CDCl3, 125 MHz) Table S10; δF (CDCl3, 470 MHz) Table S10; m/z (ESI) 684.2948 [M+Na]+ 
(C36H41F2N5NaO5 requires 684.2968). 
 
 
 
Table S10: NMR data for 4F-cycloaspeptide E 22 (a500 MHz, b126 MHz and c470 MHz, CDCl3). 
 
 
4F-cycloaspeptide 12 
Residue Position 
b 
δC /ppm (J / Hz) δH
a ppm (J / Hz) 
c 
δF ppm (J / Hz) 
Ala NH -  - 
 Cα 44.0 4.43 (1H, m) - 
 Cβ 16.7 0.53 (3H, d, J 7.0) - 
 CO 173.9 - - 
 N-Me 30.3 2.86 (3H, s) - 
 Cα 63.4 5.17 (1H, dd, J 12.0, 3.0) - 
 Cβ 3.4 3.47 (1H, dd, J 15.0, 3.0) - 
   2.94 (1H, dd, J 15.0, 12.0) - 
F-Phe(1) C1 132.4 (d, J = 3 Hz) - - 
 C2-6 130.8 (d, J = 8 Hz) 7.14 (2H, m) - 
 C3-5 115.8 (d, J = 21 Hz) 7.02 (2H, m) - 
 C4-F 162.0 (d, J = 245 Hz) - - 
 F1 - - -115.96 (tt, J = 5, 8) 
 CO 168.0 - - 
 NH - 7.21 (1H, m) - 
 Cα 48.9 4.72 (1H, ddd, J 9.0, 9.0, 6.0) - 
 Cβ 41.4 1.84 (1H, m) - 
   1.35 (1H, m) - 
Leu Cγ 25.0 1.65 (1H, m) - 
 Cδ 23.4 1.00 (3H, d, J 3.0) - 
 Cε 22.1 0.99 (3H, d, J 3.0) - 
 CO 170.0 - - 
 N-Me 39.3 2.74 (3H, s) - 
 Cα 69.9 3.82 (1H, dd, J 11.0, 4.0) - 
 Cβ 32.4 3.57 (1H, dd, J 14.0, 4.0) - 
   3.43 (1H, m) - 
F-Phe(2) C1 134.5 (d, J = 3 Hz) - - 
 C2-6 131.0 (d, J = 8 Hz) 7.14 (2H, m) - 
 C3-5 116.2 (d, J = 21 Hz) 7.02 (2H, m) - 
 C4-F 162.2 (d, J = 246 Hz) - - 
 F2 - - -115.2 (tt, J = 5, 9) 
 CO 169.8 - - 
 NH - 12.01 (1H, s) - 
 C1 115.4 - - 
ABA C2 141.6 - - 
 C3 121.0 8.90 (1H, d, J 9.0) - 
 C4 134.4 7.42 (1H, m) - 
 C5 122.5 7.02 (1H, dd, J 8.0, 8.0) - 
 C6 127.2 7.45 (1H, d, J 8.0) - 
 CO 169.8 - - 
 
 
Figure S28: Proton NMR spectra for cycloaspeptide E 5, purified from P. soppii strain NM-KO4 (PscyF) fed 
with N-methyl-L-phenylalanine 8 (bottom trace), compared to 4F-cycloaspeptide E 22, purified from P. soppii 
strain NM-KO4 (PscyF) fed with synthesised 4F-N-methyl-phenylalanine S2 (top trace). 
  
Figure S29: Carbon NMR spectra for cycloaspeptide E 5, purified from P. soppii strain NM-KO4 (PscyF) fed 
with N-methyl-L-phenylalanine 8 (bottom trace), compared to 4F-cycloaspeptide E 22, purified from P. soppii 
strain NM-KO4 (PscyF) fed with synthesised 4F-N-methyl-phenylalanine S2 (top trace). 
  
Figure S30: Fluorine NMR spectra for 4F-cycloaspeptide E 22, purified from P. soppii strain NM-KO4 (PscyF) 
fed with synthesised 4F-N-methyl-phenylalanine S2. 
Pseurotin A 25 
 
 
 
 
 
Pseurotin A 25 was purified as a white solid (4.3 mg); UV λmax nm 307; 1H NMR (CDCl3, 500 MHz) (Table S11). 
HRMS m/z calculated for C22H25NO8 431.1580; observed m/z 432.1658. 
Table S11: 1H-NMR data of the purified pseurotin A 25 compared to the literature data after a D2O wash (500 
MHz in CDCl3).
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1H NMR purified compound 1H NMR Literature* 
Position δ / ppm J / Hz) δ / ppm J / Hz 
9 4.69 (1H) s 4.70 (1H) s 
10 4.58 (1H) d (4.5) 4.59 (1H) d (4.4) 
11 4.74 (1H) dd (4.5, 9.0) 4.75 (1H) dd (4.4, 9.0) 
12 5.38 (1H) dd (9.0, 12.0) 5.28 (1H) dd (9.0, 11.0) 
13 5.68 (1H) dt (12.0, 8.0) 5.60 (1H) dt (11.0, 7.6) 
14 2.08-2.25 (2H) m 2.05-2.24 (2H) m 
15 1.02 (3H) t (7.5) 0.99 (3H) t (7.6) 
16 1.72 (3H) s 1.68 (3H) s 
19/23 8.32 (2H) d (7.5) 8.32 (2H) d (7.3) 
20/22 7.50 (2H) t (7.5) 7.49 (2H) t (7.3) 
21 7.66 (1H) t (7.5) 7.65 (1H) t (7.3) 
8-OMe 3.39 (3H) s 3.44 (3H) s 
 
Figure S31: 1H NMR spectra for pseurotin A 25, purified from P. soppii. 
Synthesis of Amino Acids 
 
General Experimental 
 
All commercially available compounds were used without further purification, with the exception of 
diisopropylamine (distilled from CaH2). All moisture or air sensitive reactions were carried out in flame-dried 
glassware under a positive pressure of nitrogen using syringe/septa techniques. Anhydrous solvents were obtained 
by passing through a modified Grubbs system of alumina columns, manufactured by Anhydrous Engineering. 
Reactions were routinely monitored by thin layer chromatography on aluminium backed silica plates (Merck DC 
Alufolien Keiselgel 60 F254). Detection was under UV light source (λmax 254 nm) or through staining with 
potassium permanganate solution (5%) with subsequent heating. Flash column chromatography was performed 
using silica gel (40-63 micron, obtained from Sigma Aldrich) as the stationary phase. 
1H, 19F and 13C NMR spectra were recorded using either a Jeol ECS300, Jeol ECS400 or Varian 400-MR 
spectrometer. The chemical shifts (δ) are reported in parts per million (ppm) and are referenced to the residual 
solvent peak. Coupling constants (J) are measured in Hertz (Hz). COSY, HSQC and HMBC were routinely used 
to define the peaks of 1H and 13C NMR spectra. 1H NMR is reported in the format: chemical shift (ppm), 
integration, multiplicity (s=singlet, d=doublet, t =triplet, q=quartet, m=multiplet, br=broad), coupling constant, 
assignment. 
Optical rotations were recorded using Bellingham and Stanley ADP220 polarimeter, irradiating with sodium D 
line (λ=589nm) and [α]D values are quoted in units 10-1 deg cm2 g-1. Infrared spectra were recorded on a Perkin 
Elmer Spectrum Two spectrometer as solids or as a thin film. Significant frequencies, ν are reported in 
wavenumber units (cm-1). 
Electrospray (ESI) mass spectra were recorded on a VG Analytical Quattro mass spectrometer. 
 
(±)-N-(tert-butoxycarbonyl)-N-methyl-p-fluorophenylalanine S2 
 
 
 
 
 
 
 
 
S1 S2 
To diisopropylamine (2.5 mL, 17.4 mmol, 3.3 equiv.) in THF (10 mL) at -15 ○C was added n-BuLi (1.45 M in 
hexane, 11.0 mL, 15.8 mmol, 3 equiv.) and the mixture stirred at -15 ○C for 30 minutes, then allowed to warm to 
0 °C. N-Boc sarcosine S1 (1.01 g, 5.3 mmol, 1 equiv.) was dissolved in THF (15 mL), and added at -10 ○C to the 
stirred LDA solution under nitrogen. After 1 h, the reaction mixture was cooled to -40 ○C and 4-fluorobenzyl 
bromide (1.6 mL, 13.0 mmol, 2.5 equiv.) added dropwise. The reaction mixture was stirred for 3 h, then quenched 
with saturated aqueous ammonium chloride (10 mL). The reaction mixture was acidified to pH 2 with HCl (1 M), 
and extracted with ethyl acetate (2 × 50 mL). The extract was dried with magnesium sulfate, and concentrated in 
vacuo to yield an orange oil. The crude material was purified by column chromatography using ethyl 
acetate/petrol/acetic acid (10-35% ethyl acetate, 1% acetic acid) to yield acid S2 (1.17 g, 74%) as an off white 
solid; δH(400 MHz, CDCl3): 7.16 (2H, m, Ar-H), 6.99 (2H, m, Ar-H), 4.81 (0.5H, dd, J 11.0, 5.0, 2-H), 4.55 (0.5H, 
dd, J 11.0, 4.0, 2-H), 3.28 (1H, m, 3-H) and 3.04 (1H, m, 3-H), 2.74 (1.5H, s, N-CH3), 2.69 (1.5H, s, N-CH3), 1.38 
 
(4.5H, s, tBu) 1.33 (4.5H, s, tBu); δF(283 MHz, CDCl3): -116.1 (m, Ar-F), -116.3 (m, Ar-F); δC(101 MHz, CDCl3): 
 
175.8, 163.1, 160.6, 156.4, 155.2, 133.3, 133.0, 130.6, 130.5, 130.4, 115.6, 115.5, 115.4, 115.3, 81.0, 80.9, 61.6, 
 
60.4, 34.6, 34.1, 32.7, 28.4, 28.3; νmax (film) 2978, 1682, 1510, 1392, 1368, 1222, 1158; HRMS (ESI) calc for 
 
C15H20FNNaO4 [M+Na]
+ 320.1269, found 320.1265. 
 
(±)-N-(tert-butoxycarbonyl)-N-methyl-m-fluorophenylalanine S3 
 
 
 
 
 
 
 
 
S1 S3 
(±)-N-(tert-butoxycarbonyl)-N-methyl-m-fluorophenylalanine S3 was prepared similarly from N-Boc sarcosine 
S1 (500 mg, 2.64 mmol) and 3-fluorobenzyl bromide (1.3 mL, 10.6 mmol, 4 equiv.), yielding the product as a 
white solid (397 mg, 51%) δH(400 MHz, CDCl3): 9.95 (1H, s, COOH), 7.26 (1H, m, Ar-H), 7.02-6.87 (3H, m, 
Ar-H), 4.84 (0.5H, dd, J 11.0, 5.0, 2-H), 4.63 (0.5H, dd, J 11.0, 4.0, 2-H), 3.32 (1H, m, 3-H), 3.00 (1H, m, 3-H), 
2.76 (1.5H, s, N-CH3), 2.70 (1.5H, s, N-CH3), 1.40 (4.5H, s, 
tBu) 1.35 (4.5H, s, tBu); δF(283 MHz, CDCl3): -113.1 
 
(m, Ar-F), -113.3 (m, Ar-F); δC(101 MHz, CDCl3): 176.2, 176.1, 164.2, 161.7, 156.3, 155.1, 140.0, 139.9, 139.8, 
 
130.2, 130.2, 130.1, 130.0, 124.9, 124.7, 116.1, 115.9, 114.0, 113.8, 113.8, 113.6, 81.1, 80.9, 61.2, 60.4, 35.1, 
 
34.6, 33.0, 32.6, 28.3, 28.3; νmax (film) 2972, 1713, 1689, 1585, 1486, 1400, 1249, 1140; HRMS (ESI) calc for 
 
C15H20FNNaO4 [M+Na]
+ 320.1269, found 320.1267. 
(±)-N-(tert-butoxycarbonyl)-N-methyl-o-fluorophenylalanine S4 
 
 
 
 
 
 
 
 
S1 S4 
(±)-N-(tert-butoxycarbonyl)-N-methyl-o-fluorophenylalanine S4 was prepared similarly from N-Boc sarcosine S1 
(500 mg, 2.64 mmol) and 2-fluorobenzyl bromide (1.3 mL, 10.6 mmol), yielding the product as a white solid (504 
mg, 64%) δH(400 MHz, CDCl3): 10.80 (1H, s, COOH), 7.25-7.13 (2H, m, Ar-H), 7.09-6.98 (2H, m, Ar-H), 4.89 
(0.4 H, dd, J 11.0, 5.0, 2-H), 4.70 (0.6 H, dd, J 11.0, 4.0, 2-H), 3.34 (1H, m, 3-H), 3.24 (0.4H, m, 3-H), 3.07 (0.6H, 
 
m, 3-H), 2.76 (1.5H, s, N-CH3), 2.71 (1.5H, s, N-CH3), 1.37 (4.5H, s, 
tBu) 1.32 (4.5H, s, tBu); δF(283 MHz, 
 
CDCl3): -118.1 (m, Ar-F); δC(101 MHz, CDCl3): 176.4, 162.7, 160.3, 156.1, 155.1, 131.7, 131.4, 128.8, 128.8, 
 
128.7, 128.6, 124.6, 124.5, 124.4, 124.3, 124.2, 115.5, 115.4, 115.3, 115.2, 81.0, 80.7, 60.2, 33.4, 32.9, 29.2, 28.3, 
 
28.2; νmax  (film) 2970, 1714, 1693, 1587, 1396, 1234, 1156, 908, 732; HRMS (ESI) calc for C15H20FNNaO4 
 
[M+Na]+ 320.1269, found 320.1278 
 
(±)-N-methyl-p-fluorophenylalanine 20 
 
 
 
 
 
 
 
 
S2 20 
Protected amino acid S2 (1.00 g, 3.36 mmol) was dissolved in DCM (4 mL) and trifluoroacetic acid (3 mL) added. 
The reaction mixture was stirred at r.t. for 16 h, then concentrated in vacuo, azeotroping with toluene (3 × 10 mL). 
The resulting white solid was washed with chloroform and diethyl ether, yielding amino acid 23 as the 
trifluoroacetic acid salt (550 mg, 53%) δH(400 MHz, D2O): 7.08-7.03 (2H, m, Ar-H), 6.92-9.85 (2H, m, Ar-H) 
4.05 (1H, t, J 6.0, 2-H), 3.11 (1H, dd, J 14.0, 6.0, 3-H), 3.03 (1H, dd, J 14.0, 6.0, 3-H), 2.52 (3H, s, N-CH3); 
δF(283 MHz, D2O): -75.7 (s, CF3COOH), -115.1 (tt, J 9.0, 5.5, Ar-F); δC(101 MHz, D2O) 170.1, 163.2, 160.8, 
 
131.1, 131.0, 128.9, 128.9, 115.7, 115.5, 61.7, 61.5, 33.7, 31.8, 31.6; νmax  (ATR) 2807, 1742, 1651, 1510, 1222, 
 
1187, 1136, 830, 727; HRMS (ESI) calc for C10H13FNO2 [M+H]
+ 198.0925, found 198.0918. 
(±)-N-methyl-m-fluorophenylalanine 19 
 
 
 
 
 
 
 
 
S3 19 
Prepared as above from protected amino acid S3 (300 mg, 1.0 mmol), to yield the product trifluoroacetic acid salt 
 
22 as a white solid(149 mg, 47%). δH(400 MHz, D2O) 7.06 (1H, m, Ar-H), 6.79-6.69 (3H, m, Ar-H), 3.97 (1H, t, 
 
J 6.0, 2-H), 3.03 (1H, dd, J 14.0, 6.0, 3-H), 2.96 (1H, dd, J 14.0, 6.0, 3-H), 2.42 (3H, s, N-CH3); δF(283 MHz, 
 
D2O) -75.9 (s, CF3COOH), -113.2 (m, Ar-F); δC(101 MHz, CDCl3): 169.9, 163.6, 161.8, 161.4, 161.2, 135.5, 
 
135.4, 130.8, 130.5, 125.0, 116.9, 116.0, 115.9, 115.8, 115.6, 114.7, 114.5, 114.0, 62.4, 61.2, 34.1, 33.9, 31.8, 
 
31.5; νmax (ATR) 3023, 2809, 1729, 1665, 1588, 1437, 1198, 1144; HRMS (ESI) calc for C10H13FNO2 [M+H]+ 
 
198.0925, found 198.0923. 
 
(±)-N-methyl-o-fluorophenylalanine 18 
 
 
 
 
 
 
 
 
S4 18 
Prepared as above from protected amino acid S4 (395 mg, 1.33 mmol), to yield the product trifluoroacetic acid 
salt 21 as a white solid (238 mg, 57%). δH(400 MHz, D2O) 7.11-6.96 (2H, m, Ar-H), 6.91-6.80 (2H, m, Ar-H), 
3.98 (1H, m, 2-H), 3.08-3.01 (2H, m, 3-H2), 2.47 (3H, s, N-CH3); δF(283 MHz, D2O) -75.8 (CF3COOH),  -117.4 
(Ar-F); δC(101 MHz, D2O) 169.9, 162.0, 159.6, 131.6, 131.4, 130.2, 124.6, 120.1, 119.9, 115.5, 115.2, 60.8, 60.6, 
 
31.9, 31.6, 28.5; νmax  (ATR) 2747, 1790, 1596, 1495, 1397, 1232, 1182, 1100, 758; HRMS (ESI) calc for 
 
C10H13FNO2 [M+H]
+ 198.0925, found 109.0924 
 
 
 
 
(±)-N-methyl-p-methylphenylalanine 15 
D 
 
 
 
 
 
 
 
 
 
(±)-N-(tert-butoxycarbonyl)-N-methyl-p-methylphenylalanine S5 was prepared similarly from N-Boc sarcosine 
S1 (500 mg, 2.64 mmol) and 2-fluorobenzyl bromide (1.3 mL, 10.6 mmol), yielding the product as a white solid 
(504 mg, 64%) which was used without purification. (±)-N-methyl-p-methylphenylalanine 18 was prepared as 
above from protected amino acid S5 (500 mg, 1.70 mmol), to yield the product trifluoroacetic acid salt 18 as a 
white solid (203 mg, 62%). δH (400 MHz, D2O 7.10 (2H, d, J 7.9 Hz, Ar-H), 7.05 (2H, d, J 7.9 Hz, Ar-H), 3.74 
(1H, t, J  6.2 Hz, 2-H), 3.05 (2H, d, J  6.2 Hz, 3-H2), 2.54 (3H, s, N-H3), 2.18 (3H, s, CH3).δC (126 MHz, D2O) 
172.6 (C=O), 137.9 (Ar), 131.1 (Ar), 129.6 (Ar-CH2), 129.3 (Ar-CH2), 64.3 (CH), 35.1 (CH2), 31.2 (N-CH3), 20.1 
 
(CH3); νmax (ATR) 3098, 3026, 2930, 1729, 1647, 1592, 1513, 1418, 1386, 1145; HRMS (ESI) calc for C11H16NO2 
 
[M+H]+ 194.1103, found 194.1176. 
 
 
 
 
(S)-(-)-N-(tert-butoxycarbonyl)-N-methyl-p-fluorophenylalanine (S)-S2 
 
 
 
 
 
 
 
 
S5 (S)-S2 
Sodium hydride (60% dispersion in mineral oil, 4.21 g, 106 mmol, 10 equiv.) was added slowly in portions over 
1 h to a solution of L-N-Boc-p-fluorophenylalanine S5 (3001 mg, 10.6 mmol) and iodomethane (6.5 mL, 106 
mmol, 10 equiv.) in THF (8 mL) at 0 ○C. The reaction mixture was allowed to warm to room temperature and 
stirred overnight. The reaction mixture was diluted with diethyl ether (40 mL) and quenched with water (15 mL). 
The layers were separated, and the aqueous layer extracted with diethyl ether (2 × 30 mL), acidified with 10% 
citric acid solution, and extracted with ethyl acetate (3 × 60 mL). The combined organic layers were dried over 
MgSO4, and concentrated in vacuo to yield an orange oil. The crude material was purified via column 
chromatography, eluting with 20-30% ethyl acetate/petrol with 1% acetic acid, to yield L-N-Me-(4-F)-Phe (S)-S2 
(3.02 g, 96%); Spectroscopic data as for S2. [�]22 -52 (c 1, CHCl3). 
D 
D 
(S)-(+)-N-methyl-p-fluorophenylalanine (S)-23 
 
 
 
 
 
 
 
 
(S)-S2 (S)-23 
Prepared as above from protected amino acid (S)-S2 (456 mg, 1.54 mmol), to yield amino acid trifluoroacetic acid 
salt (S)-23 as a white solid (157 mg, 52%). Spectroscopic data in agreement with 23. [�]22 +9.0 (c 1, 1 M HCl). 
(S)-(+)-N-ethylphenylalanine 19 
 
 
 
 
 
 
 
 
 
S6 19 
 
 
 
To a suspension of L-phenylalanine S6 (507 mg, 3.03 mmol) in methanol (6 mL) was added acetaldehyde (0.2 
mL, 158 mg, 3.58 mmol, 1.2 equiv.) and sodium cyanoborohydride (141 mg, 2.24 mmol, 0.74 equiv.) and the 
reaction mixture stirred at room temperature for 18 h. The resulting white precipitate was isolated by vacuum 
filtration and washed with methanol to yield pure (S)-N-ethylphenylalanine 19 (359 mg, 61%). δH (400 MHz, 
D2O) 7.35-7.27 (3H, m, Ar-H), 7.25-7.19 (2H, m, Ar-H) 4.23 (1H, t, J 6.5, CH), 3.29 (1H, dd, J 14.5, 5.5, ArCHH), 
3.18 (1H, dd, J 14.5, 7.0, ArCHH), 3.07 (2H, q, J 7.5, CH2), 1.17 (3H, t, J 7.5, CH3); δC(100 MHz, D2O) 170.5 
 
(C=O), 133.4 (Ar), 129.2 (Ar), 129.0 (Ar), 127.9 (Ar), 60.4  (CH), 42.1 (CH2), 34.7 (ArCH2), 10.4 (CH3); [�]22 
 
+25.0 (c 1, 2 M HCl) [lit. [�]D +33.0 (c 1, 2 M HCl)].20 
 
NMR data in accordance with literature.21 
(S)-(-)-N-(tert-butoxycarbonyl)-N,O-dimethyltyrosine (S)-S9 
 
 
 
 
 
 
 
 
 
S8 (S)-S9 
 
 
 
A solution of N-Boc-L-Tyrosine S8 (500 mg, 1.77 mmol) and methyl iodide (560 mg, 0.24 mL, 3.91 mmol) in 
THF (10 mL) at 0 ○C, sodium hydride (234 mg, 5.84 mmol) was added. After 1 h at 0 ○C the mixture was stirred 
at room temperature for 12 h. The mixture was quenched by the dropwise addition of THF/Water (1:1, 10 mL). 
The solvent was removed under reduced pressure. The residue was washed with water (20 mL) and pentane (20 
mL). The aqueous phase was acidified with citric acid (pH 2) and extracted with ethyl acetate (20 mL). The 
combined extracts were washed with aqueous sodium chloride, dried over magnesium sulphate and concentrated 
under vacuum to obtain pure (S)-S9 (501 mg, 91%) as a yellow oil. δH (500 MHz, CDCl3) 7.12 and 7.10 (2H, two 
d, J 8.5 Ar-H), 6.83 (2H, d, J 8.5, Ar-H), 4.78 (0.5H, dd, J 11.0, 5.1, 2-H), 4.55 (0.5H, dd, J 11.0, 4.5, 2-H), 3.78 
(3H, s, OCH3), 3.25 (1H, m, 3-H), 3.01 (1H, m, 3-H), 2.75 (1.5H, s, N-CH3), 2.69 (1.5H, s, N-CH3), 1.40 (4.5H, 
 
s, tBu), 1.35 (4.5H, s, tBu); δC(126 MHz, D2O) 176.4 (C=O), 176.1 (C=O) , 158.6 (ArOMe), 158.5 (ArOMe), 
 
156.6 (COOBoc), 156.2 (COOBoc), 130.1 (ArH), 130.0 (Ar), 129.6 (Ar) 129.2 (Ar), 114.2 (ArH), 114.0 (ArH), 
 
80.8 (OC(CH3)3), 80.7 (OC(CH3)3), 61.7 (CH), 60.9 (CH), 55.4 (OCH3), 34.5 (CH2), 34.0  (CH2), 33.0 (N-CH3), 
 
32.7 (N-CH3), 28.4 (OC(CH3)3), 28.3 (OC(CH3)3); [�]21 -15.3 (c 1.0, MeOH) [lit. [�]22 -16.9 (c 1.0, MeOH)].22 
D D 
 
 
 
 
(S)-(+)- N,O-dimethyltyrosine 17 
 
 
 
 
 
 
 
 
 
(S)-S9 (S)-17 
Prepared as above from protected amino acid (S)-S9 (400 mg, 1.30 mmol), to yield amino acid trifluoroacetic acid 
salt (S)-20 as a white solid (151 mg, 55%). δH (500 MHz, D2O) 7.25 (2H, d, J 8.6, Ar-H), 7.00 (2H, d, J 8.6, Ar- 
H), 4.11 (1H, t, J 6.1, 2-H), 3.83 (3H, s, OCH3), 3.28 (1H, dd, J 14.8, 6.1, 3-H), 3.23 (1H, dd, J 14.8, 6.1, 3-H), 
2.73 (3H, s, N-CH3); δC(126 MHz, D2O) 171.3 (C=O), 158.4 (ArOMe), 130.6 (ArH), 126.1 (Ar), 114.5 (ArH), 
 
62.9 (CH), 55.3 (OMe), 34.2 (CH2), 31.9 (NMe); ); [�]24 +8.1 (c 0.3, H2O) [lit. [�]20 +7.5 (c 0.3, H2O)].23 
D D 
 
 
 
 
4-Fluoro-N-(tert-butoxycarbonyl)-N-methylphenylalanine 
 
 
 
4-Fluoro-N-methylphenylalanine 
 
 
 
 
3-Fluoro-N-(tert-butoxycarbonyl)-N-methylphenylalanine 
 
 
 
3-Fluoro-N-methylphenylalanine 
 
 
 
 
2-Fluoro-N-(tert-butoxycarbonyl)-N-methylphenylalanine 
 
 
 
2-Fluoro-N-methylphenylalanine 
 
 
 
(±)-N-methyl-p-methylphenylalanine 
 
 
 
 
 
 
(S)-(+)-N-ethylphenylalanine 
 
 
(S)-(-)-N-(tert-butoxycarbonyl)-N,O-dimethyltyrosine 
 
 
 
 
 
 
  
 
(S)-(+)- N,O-dimethyltyrosine 
 
 
  
 
H. virescens injection assay 
 
 
 
Table S12. Percentage mortality of Heliothis virescens on days 1, 2, 3 and 7 after injection with cycloaspeptide 
E 5, 4F-cycloaspeptide E, spinosad as a positive control, or DMSO as a negative control. No mortality was 
observed for either of the cycloaspeptides. 
 
 
% mortality (days after injection) 
Treatment Rate 1 2 3 7 
 
Cycloaspeptide E 
 
10 ug ul-1 (n = 6) 
 
0 
 
0 
 
0 
 
0 
 
4F-Cycloaspeptide E 10 ug ul-1 (n = 6) 
 
0 
 
0 
 
0 
 
0 
Spinosad (Positive 
control) 
0.19 ug ul-1 (n = 6) 17 67 100 100 
DMSO (Negative control) Neat DMSO (n =6) 0 0 0 0 
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